Tcr2 Therapeutics Inc logo

TCRR

Tcr2 Therapeutics Inc

$3.5

Earnings Summary

Revenue
$0Mn
Net Profits
$-29.12Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Tcr2 Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Tcr2 Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Tcr2 Therapeutics Inc’s net profit fell -35.38% since last year same period to $-29.12Mn in the Q1 2022. On a quarterly growth basis, Tcr2 Therapeutics Inc has generated -4.99% fall in its net profits since last 3-months.

Net Profit Margins:

Tcr2 Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Tcr2 Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Tcr2 Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.79
EPS Estimate Current Year
-0.79

Highlights

EPS Estimate Current Quarter:

Tcr2 Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.79 - a -6.76% fall from last quarter’s estimates.

EPS Estimate Current Year:

Tcr2 Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.79.

Key Ratios

Key ratios of the Tcr2 Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.76
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.39
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Tcr2 Therapeutics Inc’s earning per share (EPS) fell -31.03% since last year same period to -0.76 in the Q1 2022. This indicates that the Tcr2 Therapeutics Inc has generated -31.03% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tcr2 Therapeutics Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tcr2 Therapeutics Inc’s return on equity (ROE) stands at -0.39.

Dividend Per Share (DPS):

Tcr2 Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.74
-0.76
-2.7%

Company Information

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Organisation
Tcr2 Therapeutics Inc
Headquarters
Cambridge, Massachusetts, US
Employees
118
Industry
Pharmaceuticals: Major
CEO
Garry Menzel